Get the Stockscreener App
4.45
3.26%
-0.15
After Hours:
4.53
0.08
+1.80%
Verve Therapeutics Inc stock is traded at $4.45, with a volume of 3.01M.
It is down -3.26% in the last 24 hours and down -18.50% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$4.60
Open:
$4.57
24h Volume:
3.01M
Relative Volume:
0.98
Market Cap:
$396.67M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-1.7181
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
+2.06%
1M Performance:
-18.50%
6M Performance:
-20.68%
1Y Performance:
-13.42%
1-Day Range:
$4.325
$4.61
1-Week Range:
$3.89
$4.63
52-Week Range:
$2.8647
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
4.45 | 388.66M | 20.65M | -192.65M | -134.39M | -2.59 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVERV - ACCESS Newswire
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st
Transcript : Verve Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st
Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance
Price T Rowe Associates Inc. MD Lowers Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $25.75 - Defense World
Dimensional Fund Advisors LP Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics: Q1 Earnings Snapshot - CT Insider
Verve Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
Verve Therapeutics (VERV) Beats Q1 EPS Estimates, Reports Signif - GuruFocus
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances - GuruFocus
Verve Therapeutics, Inc. SEC 10-Q Report - TradingView
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances Clinical Trials | VERV Stock News - GuruFocus
Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Wednesday - Defense World
Stifel Financial Corp Purchases 9,736 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Tower Research Capital LLC TRC Lowers Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street - AOL.com
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
(VERV) Investment Analysis - news.stocktradersdaily.com
Wells Fargo & Company MN Boosts Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Invesco Ltd. Buys 3,080 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release Distribution & PR Platform - ACCESS Newswire
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Did Verve Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– VERV - ACCESS Newswire
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):